The Federal Trade Commission alleged that Endo paid hundreds of millions of dollars to Impax Laboratories Inc. and Watson Laboratories, a subsidiary of Allergan PLC, to delay generic versions for two of its main pain drugs, Opana ER and Lidoderm, which together make up nearly one-fourth of the company’s branded drug revenue. The agreements, known as “pay-for-delay” settlements, delayed generic versions of the drugs until 2013, according to the FTC complaint.
Read Full Article »
